Jeito Capital is a Paris-based private equity firm founded in 2020, dedicated exclusively to clinical-stage biopharma companies developing drugs for severe diseases with high unmet medical need. The firm operates as a fully independent European fund, combining a patient-centric investment philosophy with hands-on operational support to help portfolio companies advance through clinical development and into global markets. Jeito manages approximately €1.6 billion in assets across its two funds.
Jeito focuses on clinical-stage biopharma companies, primarily based in Europe, developing breakthrough therapies in areas of strong medical demand. The firm targets oncology, obesity, autoimmune and inflammatory diseases, cardio-metabolic conditions, reproductive medicine, and neurology.
It looks for companies with strong scientific foundations, clear unmet patient need, and the potential to become global market leaders rather than short-lived acquisition targets or early-stage fire sales.
Jeito closed its second fund, Jeito II, on March 31, 2026 at €1 billion (approximately $1.2 billion), exceeding its original target and making it the largest fundraise ever achieved by a fully independent European biopharma fund. The raise triples Jeito's assets under management from the €534 million raised with Jeito I in 2021.
Jeito II will back 15 to 20 clinical-stage companies, with average investments of up to €150 million per position, staged across key value inflection points from early proof of concept through late-stage development and commercial ramp-up. The expanded capital base allows Jeito to maintain or increase ownership in portfolio companies with the highest global leadership potential, rather than getting diluted across multiple rounds.
The LP base includes sovereign and public funds such as the European Investment Bank, major pharmaceutical strategic investors, large insurers and asset managers, pension funds, family offices, university endowments, and banks from Europe, North America, and Asia. Several investors from Jeito I re-upped commitments. The fund has already deployed capital into Alveus Therapeutics, a metabolic disease company that raised a $197 million Series A in February 2026, among others.
Leadership
Dr. Rafaèle Tordjman is Founder, President, and CEO. A physician and researcher by training with a specialization in haemato-oncology, she spent nearly two decades as a venture investor at Sofinnova Partners before founding Jeito in 2020. Her prior investments included DBV Technologies, Ascendis, Lysogene, and Flexion Therapeutics. She was awarded the Chevalier de la Légion d'Honneur in 2020 and was appointed by the French government to promote France's biopharma ecosystem internationally. Sabine Dandiguian is Managing Partner with over 30 years of experience in pharma and medical devices, and serves on the boards of multiple portfolio companies. Ksenija Pavletic is a General Partner and Chief Commercial Officer with over 25 years of pharma and biotech experience, and previously served as CEO of PregLem SA, which she led to a CHF 445 million exit.
Investment Strategy
Jeito selects 15 to 20 clinical-stage companies per fund, deploying capital in stages aligned to value inflection points. The firm leads rounds, takes board seats, and provides operational support spanning clinical development, regulatory strategy, commercial planning, and market access in both Europe and the United States. Investments average up to €150 million per company, giving Jeito the capacity to support companies from early clinical proof of concept through to advanced development and pre-commercial stages.
Notable Investments
Jeito's portfolio spans oncology, immunology, neurology, and metabolic disease:
Notable Exits
The first fund generated three notable exits:
Other
Jeito has a strong diversity commitment built into its founding structure. Four out of five of the firm's Partners are women, and 62% of Jeito's overall team is female. The firm also runs W.I.T.H. (Women in the Health industry), an association founded by Dr. Tordjman to promote women in healthcare.
France
